This protein carries no "tag".
The protein has a calculated MW of 13.0 kDa. As a result of glycosylation, the protein migrates as 14-15 kDa under reducing (R) condition, and 23-25 kDa under non-reducing (NR) condition (SDS-PAGE).
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 30% ACN, 0.056% TFA. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
ActiveMax® Human Activin A, Tag Free, low endotoxin on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The bio-activity of ActiveMax® Human Activin A, Tag Free, low endotoxin (Cat. No. ACA-H421b) was determined by dose-dependent inhibition of the proliferation of MPC-11 cells. The EC50 for this effect is typically ≤ 9.5 ng/mL (Routinely tested).
Authors: Basu M, et al.
Journal: Mol Cancer 2015
Application: Cell Culture
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $250.00
Price(USD) : $650.00
Price(USD) : $4250.00
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.